Analysts See $-0.81 EPS for Summit Therapeutics plc (SMMT)

March 15, 2018 - By Michael Collier

 Analysts See $ 0.81 EPS for Summit Therapeutics plc (SMMT)

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.81 EPS on April, 4.They anticipate $0.31 EPS change or 62.00 % from last quarter’s $-0.5 EPS. After having $-0.20 EPS previously, Summit Therapeutics plc’s analysts see 305.00 % EPS growth. The stock decreased 0.72% or $0.1 during the last trading session, reaching $13.8. About 26,662 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 33.22% since March 15, 2017 and is uptrending. It has outperformed by 16.52% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 8 analysts covering Summit Therapeutic (NASDAQ:SMMT), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Summit Therapeutic had 13 analyst reports since August 19, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Thursday, June 15. The stock of Summit Therapeutics plc (NASDAQ:SMMT) has “Buy” rating given on Thursday, July 6 by H.C. Wainwright. The company was initiated on Friday, September 16 by H.C. Wainwright. The rating was maintained by Oppenheimer with “Outperform” on Friday, January 26. The firm has “Buy” rating given on Tuesday, March 6 by Canaccord Genuity. The company was downgraded on Tuesday, September 1 by Zacks. H.C. Wainwright reinitiated it with “Buy” rating and $16 target in Friday, December 1 report. RBC Capital Markets maintained the stock with “Outperform” rating in Wednesday, November 16 report. Janney Capital initiated Summit Therapeutics plc (NASDAQ:SMMT) on Tuesday, June 21 with “Buy” rating. The rating was maintained by Oppenheimer on Thursday, June 22 with “Buy”.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $200.97 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: which released: “Summit Therapeutics stock surges 50% on news of licensing deal with Sarepta” on October 04, 2016. Also published the news titled: “Summit Therapeutics PLC ADR” on June 26, 2016.‘s news article titled: “Summit Therapeutics PLC ADR SMMT (US: Nasdaq)” with publication date: February 13, 2011 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.